After the Euphoria, mRNA Cancer Vaccines Need Some "Sober Reflection."

 

On August 19, Moderna and Merck jointly announced that their personalized mRNA cancer vaccine, intismeran (development code: V940), in combination with pembrolizumab (Keytruda), met both key endpoints of recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in the Phase III INTerpath-001 trial for adjuvant treatment of high-risk melanoma.

 

This is the world's first personalized therapeutic cancer vaccine to demonstrate efficacy in a randomized controlled Phase III trial.

 

The capital markets responded swiftly: Moderna's stock surged approximately 177% at one point, adding about $44 billion in market capitalization in a single day; Merck and BioNTech, which is also developing personalized cancer vaccines, also saw double-digit stock gains.

 

But after the clinical data euphoria, commercialization challenges are beginning to emerge.

 

According to China Newsweek, citing estimates from U.S. investment bank William Blair, intismeran's wholesale acquisition cost (WAC) is approximately $475,000, equivalent to about RMB 3.18 million. Soon, the topic "cancer vaccine nearly $500,000 per shot" trended on social media.

 

And this is precisely what makes this product truly worth paying attention to.

 

Because when a highly personalized therapeutic vaccine reaches Phase III success and stands at the doorstep of commercialization, the question is no longer just "does it work?" — but rather: can this drug, manufactured individually for each patient, ever become a scalable business?

 

Chapter 1: Where Does the Cost of mRNA Cancer Vaccines Come From?

 

First, let's clarify a concept that is easily misunderstood. The $475,000 figure is only an estimated wholesale acquisition cost for intismeran; it does not equal the total treatment cost ultimately borne by patients. In fact, the clinical study that generated the excitement is a combination therapy — intismeran must be used with Keytruda, and Keytruda alone already costs around $100,000 per year of treatment.

 

So what patients actually face is not a $475,000 vaccine shot, but a complete treatment regimen of "personalized cancer vaccine + immune checkpoint inhibitor."

 

But this does not change the fact that the cost of personalized vaccines is indeed much higher than that of traditional drugs. There are two reasons.

 

One is the R&D cost shared by all innovative drugs. According to Deloitte estimates, the average cost of developing a new drug for the world's top 20 pharmaceutical companies reached $2.23 billion in 2024, including sunk costs from numerous failed R&D projects.

 

Moderna itself is a typical example. In 2025, the company's revenue was approximately $1.9 billion, but it posted a net loss of about $2.8 billion, with R&D expenses of about $3.1 billion.

 

Ultimately, innovative drugs must cover their upfront investments through commercial returns.

 

But if we only use R&D costs to explain the $475,000 price tag, it's clearly not enough. What really drives up intismeran's cost is the "one drug per patient" manufacturing model.

 

Traditional drugs can be produced in millions of doses using a fixed formula — the larger the production scale, the lower the unit cost. Intismeran is completely different.

 

It requires screening tumor-specific neoantigens based on the genetic mutations in each patient's tumor tissue, and then designing the corresponding mRNA accordingly. The entire process includes tumor sampling, sequencing, neoantigen screening, sequence design, mRNA synthesis, LNP encapsulation, and quality control.

 

In other words, each patient essentially requires an independent production process.

 

According to estimates by Dr. Zhan Qilin, Chief Physician of the Hematology and Oncology Department at Shanghai Public Health Clinical Center, the manufacturing cost per patient for such drugs could exceed $100,000, and it takes 6 to 9 weeks from sampling to the first injection.

 

This means it is difficult to simply replicate the economies of scale of traditional drugs.

 

Producing 1 million doses of a traditional drug does not entail 1 million independent personalized R&D processes; but producing personalized vaccines for 1 million different patients means handling 1 million different production tasks.

The more personalized the product, the harder it is to scale. This is the real paradox of personalized medicine. It aims to "customize for everyone," but commercialization demands "as much standardization as possible."

 

Therefore, future cost competition for such products may not depend primarily on how much cheaper a particular raw material becomes, but on whether the entire production system can be engineered: can neoantigen prediction be faster, can the design process be automated, can the production cycle be shortened, can equipment utilization be improved, and can quality control be standardized?

 

The $475,000 price tag is less a bill for a "blockbuster drug" than a cost ledger for the industrialization of personalized therapies.

 

Chapter 2: Is the Market Too Optimistic About mRNA Cancer Vaccines?

 

High price is not an inherent sin of innovative drugs.

 

How much a drug can sell for ultimately depends on how much clinical value it creates and how much the payment system is willing to pay for that value.

 

What is truly dangerous is the alternative scenario: clinical success, but price and production model keep patients out of the market.

 

This is not without precedent.

 

Provenge, approved in 2010, was the world's first therapeutic cancer vaccine. It also used a personalized manufacturing model, requiring cells to be extracted from the patient, processed ex vivo, and reinfused. High cost, complex logistics, and personalized manufacturing together made commercialization difficult, and the developer, Dendreon, ultimately went bankrupt.

 

Clinical value has been validated, but how to bridge the gap between high manufacturing costs, limited production capacity, and patient affordability remains a persistent challenge for the entire industry.

 

What makes intismeran truly different is that it may be the first time a personalized cancer vaccine has been advanced from a "technical concept" to a "commercial product."

 

This is also why the capital markets were willing to assign a high valuation so quickly.

 

In melanoma, Keytruda relieves immunosuppression, while the personalized mRNA vaccine further trains the immune system to recognize tumor-specific neoantigens.

 

Dr. Harrison Nguyen, Clinical Associate Professor of Dermatology and Health Economics at the University of Houston College of Medicine and founder of Harrison Dermatology & Research Group, believes this means personalized cancer vaccination is moving from a scientific concept to a treatment modality with genuine clinical applicability.

 

But even optimists have not skipped a critical premise: full data still matters.

 

What will truly determine this product's commercial value is not just the magnitude of risk reduction, but also absolute benefit, toxicity, production cycle, patient selection, treatment cost, and ultimately whether it can translate into an overall survival advantage.

 

So what intismeran needs to answer now is not "is there a market?"

 

Rather: how big is this market really?

 

The most明确的 commercialization scenario at present is adjuvant treatment for high-risk melanoma. Patients must undergo tumor resection, obtain qualified tumor tissue, and meet the corresponding clinical conditions.

 

According to International Agency for Research on Cancer (IARC) data, there were 330,000 new cases of melanoma worldwide in 2022, with the highest numbers in the U.S., Germany, and the UK, corresponding to age-standardized incidence rates of approximately 15–16.5 (ASR/100,000), compared to a global average of only 3.2.

 

This means that melanoma patients are distributed in a highly uneven geographical pattern, and from a global market perspective, this is not a broad indication.

 

A small cancer type, combined with a narrow indication, means it will be difficult for intismeran to quickly amortize production costs through patient volume.

 

It is more likely to follow a path of "high unit price, high value, slow volume growth."

 

But what the capital markets are clearly looking at is not just today's melanoma.

 

Barclays analysts project that by 2035, intismeran could generate approximately $3 billion in annual sales in melanoma alone.

 

William Blair analyst Myles Minter predicts that if Moderna and Merck split 50/50, intismeran's peak sales could reach $5.4 billion in melanoma alone.

 

The greater source of excitement comes from indication expansion.

 

Moderna and Merck are advancing multiple clinical trials covering various tumor types, including renal cancer and lung cancer. This is intismeran's真正的 commercial proposition: is it a melanoma drug, or a personalized therapy platform that can be continuously replicated across different cancer types?

 

Two answers correspond to completely different valuation logics.

 

If it only succeeds in a few cancer types, the market ceiling will soon become apparent.

 

If it can replicate efficacy across multiple cancer types while continuously reducing costs through platform-based manufacturing, then today's $475,000 may just be an early-stage coordinate in its commercial journey.

 

It's therefore not surprising that market forecasts are now showing明显的 divergence. Optimists see a platform.

 

Analysts view the Phase III data as important validation of the mRNA technology platform and the commercial potential of personalized cancer vaccines. Morningstar even raised the probability of success in melanoma to 100%, and increased the expected probability of approval in lung cancer from 40% to 60%.

 

Cautious observers, however, look at valuation.

 

Evercore ISI's Cory Kasimov believes Moderna's new valuation already reflects optimism far beyond what public data can support.

 

Leerink Partners analyst Daina Graybosch was even more direct: the market reaction may be overly optimistic. Her concern is that if the manufacturing cost per patient remains higher than standard biologics over the long term, replicating this model to more indications is not something that can be taken for granted.

 

The two perspectives are not actually contradictory.

 

Intismeran may simultaneously be a monumental scientific breakthrough and a business that has yet to prove it can scale.

 

What is truly worth watching in the future are two curves. One is the efficacy curve: can it move from melanoma to more cancer types? The other is the cost curve: can it continue to decline from $475,000?

 

The former determines whether it has value; the latter determines how many patients that value can ultimately reach.

 

Chapter 3: China's Opportunity Is Not Just About Making a "Chinese Version of Intismeran"

 

If mRNA cancer vaccines eventually enter China, the questions become even more real.

 

CAR-T has already proven one thing: between clinical value and patient accessibility, there is no naturally open channel.

 

For a highly personalized mRNA cancer vaccine, this issue may be even more pronounced.

 

Because traditional drugs can reduce unit cost by increasing production volume, but the "one drug per patient" model inherently makes it difficult to simply rely on volume for price reduction.

 

Therefore, the first problem Chinese companies need to solve may not be "how to make a Chinese version of intismeran," but rather: how to make a production model like intismeran's cheaper.

 

There is a whole value chain of opportunities here.

 

On one hand, there are foundational technologies and intellectual property. mRNA drugs involve multiple key steps including capping, nucleoside modification, and LNP delivery. Core patent barriers directly affect technology routes and manufacturing costs. Resolving key patent barriers in capping and ionizable lipids could reduce mRNA dosage and further lower costs.

 

On the other hand, there is the industrial chain. Currently, the core barriers of mRNA drugs are mainly concentrated in mRNA sequence patents and LNP delivery systems. China has already formed a relatively complete industrial chain, from nucleotide raw materials, lipid excipients, and manufacturing equipment, to GMP-grade synthesis, LNP encapsulation, and CDMO services.

 

Securities Times, citing professional opinions, noted that China's mRNA vaccine technology still has many shortcomings, mainly due to insufficient time accumulation and relatively weak investment. The core bottlenecks lie in mRNA sequence patents and the technological gap in LNP delivery systems.

 

But this precisely illustrates that Chinese companies do not necessarily need to establish technological advantages in every link. A more realistic industrial path is: overseas giants validate the technology route, and Chinese companies leverage their supply chain, manufacturing, and engineering capabilities to make the validated route faster and cheaper.

 

A similar scenario has already played out in CAR-T industrialization. Chinese companies did not reinvent CAR-T, but through process optimization, domestic supply chains, production efficiency improvements, and business model adjustments, they have gradually built their own industrialization capabilities.

 

mRNA cancer vaccines may follow a similar path.

 

Whether "one drug per patient" can truly become a sustainable business model in the future may depend less on scientists' imagination and more on engineers' patience with costs.

 

Whoever can shorten the personalized process, standardize production, improve quality control efficiency, and reduce the unit cost per patient will be more likely to determine how many patients this technology can ultimately reach.

 

It could even be said that for the Chinese market, this may be more important than "who develops the Chinese version of intismeran first." Because real industrial competition will not ultimately stop at a single drug. It will land on a production system.

 

— In Conclusion —

 

The Phase III success of intismeran is certainly worth celebrating.

 

It is the first time mRNA technology has proven its value in cancer treatment with Phase III randomized controlled data, and it has brought personalized therapeutic cancer vaccines to the doorstep of commercialization for the first time.

 

But moving from the lab to the market, clinical success is only the first door. Beyond it lie cost, production capacity, manufacturing cycle, payment, and patient scale.

 

Clinical success is the starting point of value realization, not the end. So the $475,000 figure is not really about "is it expensive or not." It's about whether this number will come down in the future.

 

If the production cycle can be shortened, personalized design can be further automated, AI can improve neoantigen prediction efficiency, and the LNP and mRNA industrial chain continues to mature, today's seemingly unbearable cost may gradually become an engineering problem that can be solved.

 

This may also be the biggest difference between intismeran and previous personalized therapies.

 

Its scalability may not come from "producing more of the same drug." But rather: using the same platform to produce more different drugs, faster and at lower cost.

 

Therefore, the debate around $475,000 is superficially about whether one vaccine shot is worth the price, but what it really asks is a much bigger industrial question:

 

As innovative drugs become increasingly personalized, can we still find a way to make "customized for everyone" and "affordable for more people" simultaneously true?

 

Intismeran has proven the first half of that sentence.

 

As for the second half — that is its true commercialization test.

 

References:

• Cancer vaccine win restores Wall Street's faith in Moderna; BioPharma Dive

• Cancer vaccine ignites capital markets, lifting four A-share pharmaceutical sectors; Securities Times

• Moderna cancer vaccine, nearly $500,000 per shot; Jiemian News

• mRNA cancer vaccine breaks ice, concept stocks soar: technology works but bottlenecks remain; Yicai

• Personalized Vaccine May Slash Melanoma Recurrence Rates; The Dermatology Digest